Baxter Sheds Poorly Performing Blood Products Line For $540 Mil.
This article was originally published in The Gray Sheet
Executive SummaryBaxter will sell its blood collection and processing business to a pair of investment firms for $540 mil., it announced Oct. 3
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.